This retrospective analysis describes the administration of sotrovimab in 32 children (22 aged 12-16 years old; 10 aged 1-11 years old) who were at high risk of deterioration to severe COVID-19 disease. We provide dosing suggestions and demonstrate the feasibility of sotrovimab use in the younger pediatric population (<12 years old and <40 kg).

Download full-text PDF

Source
http://dx.doi.org/10.1093/jpids/piad020DOI Listing

Publication Analysis

Top Keywords

high risk
8
severe covid-19
8
covid-19 disease
8
sotrovimab young
4
young pediatric
4
pediatric patients
4
patients high
4
risk progression
4
progression severe
4
disease retrospective
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!